Isotechnika Pharma Inc IPHAF

RE: Problem with ISA's marketing strategy

[antoninus]

Based on what I could glean, it was farticulated to me that the market for psoriasis is too fractured, and that isa will never recoup the 200 million they spent advancing the psoriasis trials.

as for lux being taken out- where did you get that info?

per a TX partner, I have long said that without a proper partner for this indication, we are limited in our upside.